Want to see HK:6998 full AI Analyst Report?
Genor Biopharma Holdings Limited (6998) AI Stock Analysis
Genor Biopharma Holdings Limited
(HKEX:6998)
The score is led by a strong 2025 financial inflection and attractive earnings valuation (low P/E), but it is held back by weak technical momentum (below key moving averages with negative MACD) and the need to prove durability after prior years of volatile/weak revenue and a sharp rise in debt.
Genor Biopharma Holdings Limited (6998) vs. iShares MSCI Hong Kong ETF (EWH)
- Market Cap
- HKD 3.26B
- Dividend Yield
- ―
- Average Volume (3M)
- 827.00K
- Price to Earnings (P/E)
- 4.5
- Beta (1Y)
- 0.70
- Revenue Growth
- 1417.68%
- EPS Growth
- 660.14%
- Country
- Hong Kong
- Employees
- 1,499
- Sector
- General
- Sector Strength
- 55
- Industry
- Biotechnology
Genor Biopharma Holdings Limited Business Overview & Revenue Model
Company Description
Genor Biopharma Holdings Limited operates as a biopharmaceutical enterprise, concentrating its efforts on the research, development, and commercialization of therapeutic agents for oncology and autoimmune disorders, both within China and globally. It...
How the Company Makes Money
Genor Biopharma primarily makes money through (1) sales of biologic drugs it commercializes (where revenue is recognized from product sales to distributors, hospitals, or other customers), and (2) out-licensing/licensing arrangements for its drug can...
Genor Biopharma Holdings Limited Financial Statement Overview
Summary
Financials show a clear 2025 turnaround (revenue ~2.42B, net margin ~16%, EBIT margin ~26%) and positive cash generation (operating cash flow ~452M; free cash flow ~404M). However, the prior multi-year pattern included losses and highly volatile/limited revenue history, and debt rose sharply to ~1.49B (debt-to-equity ~0.39), so durability of the improvement is not yet proven.
Income Statement
68PositiveBalance Sheet
63PositiveCash Flow
56Neutral| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 3.56B | 2.70B | 2.76B | 0 | 18.53M | 0 |
| Gross Profit | 2.23B | 1.76B | 1.78B | -84.96M | -45.04M | -73.21M |
| EBITDA | 1.09B | 933.65M | 907.79M | -694.88M | -860.58M | -1.05B |
| Net Income | 430.60M | 433.01M | 420.56M | -745.17M | -849.15M | -1.04B |
Balance Sheet | ||||||
| Total Assets | 6.09B | 6.61B | 1.29B | 1.45B | 2.12B | 2.86B |
| Cash, Cash Equivalents and Short-Term Investments | 913.17M | 1.06B | 1.06B | 1.17B | 1.59B | 2.20B |
| Total Debt | 1.18B | 1.49B | 911.00K | 7.16M | 28.59M | 57.41M |
| Total Liabilities | 2.11B | 2.75B | 138.05M | 256.18M | 309.87M | 369.73M |
| Stockholders Equity | 3.98B | 3.86B | 1.15B | 1.19B | 1.80B | 2.49B |
Cash Flow | ||||||
| Free Cash Flow | 546.51M | 404.05M | -123.55M | -426.15M | -590.56M | -695.13M |
| Operating Cash Flow | 600.32M | 451.73M | -121.98M | -425.12M | -577.61M | -623.74M |
| Investing Cash Flow | 1.54B | 1.24B | 8.01M | 5.99M | -12.94M | -54.26M |
| Financing Cash Flow | -952.27M | -744.78M | -1.56M | -6.82M | -57.39M | 17.57M |
Genor Biopharma Holdings Limited Technical Analysis
Price Trends
Market Momentum
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6998, the sentiment is Negative. The current price of 1.62 is below the 20-day moving average (MA) of 1.65, below the 50-day MA of 1.65, and below the 200-day MA of 2.19, indicating a bearish trend. The MACD of -0.02 indicates Positive momentum. The RSI at 45.74 is Neutral, neither overbought nor oversold. The STOCH value of 46.43 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6998.
Genor Biopharma Holdings Limited Peers Comparison
Overall Rating
- HK:699859Neutral
HK:218157Neutral
HK:116748Neutral
HK:368145Neutral
HK:699645Neutral
HK:154144Neutral
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| HK:6998 | 59Neutral | HKD 3.26B | 4.48 | 10.99% | ― | 1417.68% | 660.14% |
| HK:2181 | 57Neutral | HKD 1.79B | 17.80 | 48.25% | ― | 88.38% | ― |
| Sector * | 55Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% |
| HK:1167 | 48Neutral | HKD 3.62B | 6.00 | 47.76% | ― | 286.20% | ― |
| HK:3681 | 45Neutral | HKD 1.47B | -6.85 | -41.81% | ― | ― | -4.24% |
| HK:6996 | 45Neutral | HKD 1.80B | 29.59 | 6.51% | ― | 605.95% | ― |
| HK:1541 | 44Neutral | HKD 1.25B | -4.64 | -32.32% | ― | 28.93% | 27.27% |
* General Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| HK:6998 | Genor Biopharma Holdings Limited | 1.62 | -1.51 | -48.24% | |
| HK:6996 | Antengene Corporation Limited | 2.79 | -2.33 | -45.51% | |
| HK:1167 | Jacobio Pharmaceuticals Group Co., Ltd. | 4.60 | -2.66 | -36.64% | |
| HK:2181 | Mabpharm Limited | 0.43 | -0.09 | -16.35% | |
| HK:3681 | SinoMab Bioscience Ltd. | 1.07 | -0.70 | -39.55% | |
| HK:1541 | ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H | 2.90 | -6.15 | -67.96% |
Genor Biopharma Holdings Limited Corporate Events
Edding Genor Chairman to Boost Stake as Company Launches Share Buyback
Edding Genor Group Holdings Limited has announced that chairman and chief executive officer Ni Xin will personally purchase additional shares in the company on the open market, investing up to USD1,000,000 starting 31 August 2026, subject to regulato...
Edding Genor Posts Solid Interim Revenue as It Deepens Push Into Breast Cancer Therapies
Edding Genor reported interim results for the six months to 30 June 2026, its first full period after a strategic merger, posting revenue of RMB872.7 million, an adjusted EBITDA of RMB204.8 million, and a narrowed net loss of RMB65.9 million, support...
Edding Genor Warns of First‑Half Loss as Drug Procurement Hits Sales
Edding Genor Group Holdings has warned that it expects first‑half 2026 revenue to fall to about RMB850 million to RMB900 million from RMB1.14 billion a year earlier, and to swing to a net loss of RMB60 million to RMB70 million from a RMB114.6 m...
Edding Genor Sets Board Meeting to Review Interim Results and Dividend Plan
Edding Genor Group Holdings Limited has scheduled a board meeting for 28 August 2026 to review and approve interim results for the six months ended 30 June 2026. The board will also consider the publication of these results, which will provide invest...
Edding Genor Advances GB268 Breast Cancer Trial with First Patient Dosed
Edding Genor Group Holdings Limited has reported the successful first dosing of a subject in its Phase Ib/II clinical trial of GB268, a PD-1/CTLA-4/VEGF trispecific antibody for locally advanced unresectable or metastatic breast cancer, including TNB...
Edding Genor’s Jing Zhu Da Sub-Licensing Deal Collapses After Upstream License Termination
Edding Genor Group Holdings Limited has disclosed that its 2023 sub-license agreement for the oncology drug Jing Zhu Da in Mainland China can no longer be performed after Syndax Pharmaceuticals terminated an original 2013 license held by EOC Pharma (...
Edding Genor Realises US$48.4 Million from Sale of Candid Stake After UCB Takeover
Edding Genor Group Holdings has disclosed the disposal of its entire 2.29% equity stake in Candid Therapeutics following Candid’s acquisition by Belgian drugmaker UCB, receiving US$48.4 million as part of the cash consideration. The transaction...
Edding Genor Launches Up to 10% Share Buyback Ahead of 2027 AGM
Edding Genor Group Holdings Limited has announced that its board will exercise a shareholder-approved mandate to repurchase up to 10% of the company’s issued shares on the open market before the 2027 annual general meeting. The repurchased shar...
Edding Genor Wins NMPA Nod for Phase Ib/II Trial of Trispecific Breast Cancer Antibody GB268
Edding Genor Group Holdings Limited has secured approval from China’s National Medical Products Administration for an Investigational New Drug application to conduct a Phase Ib/II clinical trial of GB268 in locally advanced unresectable or meta...
Edding Genor shareholders back board, accounts and 10% buyback mandate at AGM
Edding Genor Group Holdings Limited reported that all resolutions at its 26 June 2026 annual general meeting in Shanghai were approved by poll, with 1,990,748,274 shares eligible to vote after excluding treasury stock. The meeting, chaired by chairma...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 21, 2026